Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
MSD’s new COX-2 inhibitor Arcoxia approved
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Dec 29, 2014 07:55:21
MSD Korea got marketing approval for Arcoxia, its new COX-2 inhibitor, from the Ministry of Food and Drug Safety on December 24.

Arcoxia, generically known as etoricoxib, belongs to the same family as Vioxx that was withdrawn after safety issues of cardiovascular events were raised. The marketing approval of Arcoxia has been delayed due to the concern that Arcoxia may have the same safety issue as Vioxx.

The concern about adverse reactions of Arcoxia still lingers, but it is known that it was highly effective for relieving symptoms of osteoarthritis.

Industry experts said Arcoxia would face tough competition with Celebrex and later with generic versions of Celebrex. It will take time until Arcoxia is put on the market after price negotiation.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com